More importantly, several studies reported that CIP2A could serve as a prognostic indicator for various solid and hematological tumors, including non-small cell lung cancer [12], colon cancer [13], breast cancer [14], ovarian cancer [15], renal cancer [16], tongue cancer [17], esophageal adenocarcinoma [18], bladder cancer [19], and chronic myeloid leukemia [20]. This evidence concerns the gene CIP2A and urinary bladder carcinoma.